About
Mark Carlton, PhD, is a biotech and pharmaceutical R&D executive focused on neuroscience and CNS drug discovery. He serves as Chief Scientific Officer at Cerevance, and the company says he previously co-founded Paradigm Therapeutics and served as President and CSO of Takeda Pharmaceutical's Cambridge UK site. He appears most relevant as a scientific and industry operator in neurodegenerative and psychiatric therapeutics rather than as an investor.
Areas of interest
biotechneuroscienceCNS disordersneurodegenerative diseasepsychiatrydrug discovery